madman
Super Moderator
* Labs collected include total testosterone (TT), free testosterone (fT), estradiol (E2), hematocrit (Hct), hemoglobin (Hg), triglycerides (TG), total cholesterol (TC), high density lipoproteins (HDL) and low density lipoproteins (LDL). Labs were collected before 11am, fasting, using LCMS and equilibrium dialysis for the lipid panels.
* We found no statistically significant difference in the change of triglyceride (p=0.903, SD=39.3), total cholesterol (p=0.783, SD=14.01), and low-density lipoprotein (p=0.447, SD=24.3) lab values before and after treatment with CC. We did however find a statistically significant decrease in high-density lipoprotein lab values (p<0.001, SD=12.95).
* Men on CC therapy for hypogonadism showed a statistically significant decrease in HDL levels after 4 weeks on clomid.
CLOMIPHENE CITRATE THERAPY EFFECTS ON LIPID PANELS IN MEN WITH HYPOGONADISM
Ahsan Siddiqui, Thairo Pereira, Lucas Amorim*, Helen L. Bernie,Indianapolis, IN
INTRODUCTION AND OBJECTIVE
Clomiphene citrate (CC) is a selective estrogen receptor modulator used to improve testosterone production in men with hypogonadism. CC is commonly used in Andrology clinics with known side effects such as elevated estradiol levels and gynecomastia. There are several case studies of severe hypertriglyceridemia in women on CC, but little data exists evaluating the impact of CC on lipid panels in men. This study aims to assess the impact of treatment with CC on lipid panels in hypogonadal men.
METHODS
A retrospective review was performed on patients presenting to a Men’s Health clinic for hypogonadism from January 2020 - September 2024 that had complete lab panels pre- and post-CC treatment. Pre-treatment endocrine and lipid profiles were compared to panels collected 4 weeks after beginning treatment. Labs collected include total testosterone (TT), free testosterone (fT), estradiol (E2), hematocrit (Hct), hemoglobin (Hg), triglycerides (TG), total cholesterol (TC), high density lipoproteins (HDL) and low density lipoproteins (LDL). Labs were collected before 11am, fasting, using LCMS and equilibrium dialysis for the lipid panels.
RESULTS
52 men with a mean age of 42.4 had complete lab data and were included in this study. Mean TT levels were 322 ng/dl pre-CC and 502 ng/dl post-CC treatment. Pre-CC TG, TC, HDL, and LDL means were 141.9, 172.4, 43.3, and 100.9, respectively. Post-CC TG, TC, HDL, and LDL means were 140.9, 171.5, 40.1, and 103.2, respectively. We found no statistically significant difference in the change of triglyceride (p=0.903, SD=39.3), total cholesterol (p=0.783, SD=14.01), and low-density lipoprotein (p=0.447, SD=24.3) lab values before and after treatment with CC. We did however find a statistically significant decrease in high-density lipoprotein lab values (p<0.001, SD=12.95).
CONCLUSION
Men on CC therapy for hypogonadism showed a statistically significant decrease in HDL levels after 4 weeks on clomid. While many men remain on clomid for an indeterminate time frame this is an area that deserves further investigation with larger population samples to determine the significance of this finding and long-term outcomes of CC on lipid profiles.
* We found no statistically significant difference in the change of triglyceride (p=0.903, SD=39.3), total cholesterol (p=0.783, SD=14.01), and low-density lipoprotein (p=0.447, SD=24.3) lab values before and after treatment with CC. We did however find a statistically significant decrease in high-density lipoprotein lab values (p<0.001, SD=12.95).
* Men on CC therapy for hypogonadism showed a statistically significant decrease in HDL levels after 4 weeks on clomid.
CLOMIPHENE CITRATE THERAPY EFFECTS ON LIPID PANELS IN MEN WITH HYPOGONADISM
Ahsan Siddiqui, Thairo Pereira, Lucas Amorim*, Helen L. Bernie,Indianapolis, IN
INTRODUCTION AND OBJECTIVE
Clomiphene citrate (CC) is a selective estrogen receptor modulator used to improve testosterone production in men with hypogonadism. CC is commonly used in Andrology clinics with known side effects such as elevated estradiol levels and gynecomastia. There are several case studies of severe hypertriglyceridemia in women on CC, but little data exists evaluating the impact of CC on lipid panels in men. This study aims to assess the impact of treatment with CC on lipid panels in hypogonadal men.
METHODS
A retrospective review was performed on patients presenting to a Men’s Health clinic for hypogonadism from January 2020 - September 2024 that had complete lab panels pre- and post-CC treatment. Pre-treatment endocrine and lipid profiles were compared to panels collected 4 weeks after beginning treatment. Labs collected include total testosterone (TT), free testosterone (fT), estradiol (E2), hematocrit (Hct), hemoglobin (Hg), triglycerides (TG), total cholesterol (TC), high density lipoproteins (HDL) and low density lipoproteins (LDL). Labs were collected before 11am, fasting, using LCMS and equilibrium dialysis for the lipid panels.
RESULTS
52 men with a mean age of 42.4 had complete lab data and were included in this study. Mean TT levels were 322 ng/dl pre-CC and 502 ng/dl post-CC treatment. Pre-CC TG, TC, HDL, and LDL means were 141.9, 172.4, 43.3, and 100.9, respectively. Post-CC TG, TC, HDL, and LDL means were 140.9, 171.5, 40.1, and 103.2, respectively. We found no statistically significant difference in the change of triglyceride (p=0.903, SD=39.3), total cholesterol (p=0.783, SD=14.01), and low-density lipoprotein (p=0.447, SD=24.3) lab values before and after treatment with CC. We did however find a statistically significant decrease in high-density lipoprotein lab values (p<0.001, SD=12.95).
CONCLUSION
Men on CC therapy for hypogonadism showed a statistically significant decrease in HDL levels after 4 weeks on clomid. While many men remain on clomid for an indeterminate time frame this is an area that deserves further investigation with larger population samples to determine the significance of this finding and long-term outcomes of CC on lipid profiles.
